Developing Rapid Translational Biomarkers to Confirm Target Engagement Early & De-Risk the Move into Phase II
2:30 pm - Wednesday 17th March 2027
- Identifying urine, plasma and PBMC markers capable of producing pharmacodynamic readouts within weeks
- Separating target engagement biomarkers from biomarkers expected to predict clinical benefit
- Building translational biomarker strategies into programs before first-in-human studies begin